Navigation Links
Anthrax paralyzes immune cells with lethal toxin, UF research shows

University of Florida researchers have revealed how the inhaled form of anthrax paralyzes the body's defenses and prevents immune cells from reaching the site of infection.

Anthrax killed five people in 2001 when letters containing the bacteria's spores were sent through the mail. The UF findings, published last week in the EMBO Journal, may lead to quicker diagnoses for anthrax victims.

The disease causes flu-like symptoms that can take weeks to develop, according to the Centers for Disease Control and Prevention. But once the first symptom appears, the disease progresses rapidly and patients often die from shock before they realize they have more than a common cold. The current method of detecting anthrax relies on lab cultures that can take days to complete.

"We're looking for approaches to detect anthrax earlier in the blood," said Russell During, Ph.D., a postdoctoral fellow at UF's College of Medicine. "We're trying to develop a test that would allow detection within two or three hours of the bugs entering the blood and secreting toxins."

Once inhaled, anthrax releases a lethal toxin that immobilizes the white blood cells that normally seek and destroy invading bacteria. Just traces of the toxin can slow movement of these cells, called neutrophils, by 50 percent, UF researchers discovered.

"Neutrophils have to get to the infection to kill anything. If you paralyze them so they don't move, they can't protect you," said Fred Southwick, M.D., division chief of infectious diseases at the UF College of Medicine and the study's lead author.

But exactly how the anthrax toxin wards off neutrophils has puzzled scientists for years. Immune cells rely on rod-shaped filaments called actin to propel them toward an infection. In a previous study, Southwick found that the toxin prevents actin assembly, leaving neutrophils stuck in the mud.

"Actin is important because it's the motor that causes neutrophils to
'"/>

Source:University of Florida


Page: 1 2 3

Related biology news :

1. Study Models Impact Of Anthrax Vaccine
2. Anthrax test, developed by army and CDC, receives FDA approval
3. Anthrax inhibitors identified by Burnham team
4. Anthrax stops body from fighting back, study shows
5. Anthrax spores may survive water treatment
6. Anthrax inhibitor counteracts toxin, may lead to new therapeutics
7. Anthrax attack posed greater potential threat than thought
8. Fox Chase Cancer Center scientists identify immune-system mutation
9. Genetically modified natural killer immune cells attack, kill leukemia cells
10. Studies reveal methods viruses use to sidestep immune system
11. Jumping gene helps explain immune systems abilities
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anthrax paralyzes immune cells with lethal toxin research shows

(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... 7, 2008 The Global Innovation Imperatives (Gii) ... for their first session at the American Chemical ... Gii, a joint collaboration between the ACS Committee ... Industry, seeks to combat worldwide health, environmental and ...
... is a poorly understood condition that incapacitates and affects the ... In the US, it affects approximately six million women and ... It is a chronic painful disease which occurs when ... the area of the ovaries and fallopian tubes, but can ...
... the fact that millions of Americans are believed to have ... to treat many of these people. That is due in ... are varied and complex, ranging from chronic allergies, viral infection, ... percent of Americans have lost their sense of smell and ...
Cached Biology News:At ACS' national meeting, global initiative set to tackle water issues 2New study finds uncontrollable stress worsens symptoms of endometriosis 2New study finds uncontrollable stress worsens symptoms of endometriosis 3For some who have lost their sense of smell, a once popular asthma drug could help 2For some who have lost their sense of smell, a once popular asthma drug could help 3
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... ... Countries, - Competitors Precluded from Immediate Commercialization of Competitive ... Products, ... TSX.V.NTB) announces that the,European Patent Office (EPO) granted on May 31st 2007 Neptune,s composition,of ...
... Expected to Yield Multiple New Drug Products for Aida,s ... ... Calif., March 27 Aida,Pharmaceuticals, Inc (OTC Bulletin Board: AIDA) today ... Jiangsu,Institute of Microbiology Co., Ltd. ("JSIM") Aida,s subsidiary, Hanzhou,Aida Pharmaceuticals Co., ...
... through conversion of agricultural ... products into advanced materials, COLUMBUS, Ohio, ... representing a wide range of expertise in the,fields of chemicals, ... Chemicals, Polymers, and Advanced Materials Task Force. The,creation of the ...
Cached Biology Technology:Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 2Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 3Aida Acquires High-Level Research Institute in China 2Ohio Task Force Begins Mission of Creating a New 21st Century Industry 2Ohio Task Force Begins Mission of Creating a New 21st Century Industry 3
Hamster serum...
... Dye Pack, 12 x Cy5. The ... for microarray labeling.Higher reactivity Cy3 and ... per vial, at > 75% reactive ... and packed in foil packs for ...
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
... Power Supply, 1. 300 V, 400 ... constant current modes.Single-unit increments in settings ... for submarine, mini vertical, and standard ... semidry and mini tank blotting applications. ...
Biology Products: